IL235337A0 - Treatment of sclerosis by a dose of laquinimod - Google Patents
Treatment of sclerosis by a dose of laquinimodInfo
- Publication number
- IL235337A0 IL235337A0 IL235337A IL23533714A IL235337A0 IL 235337 A0 IL235337 A0 IL 235337A0 IL 235337 A IL235337 A IL 235337A IL 23533714 A IL23533714 A IL 23533714A IL 235337 A0 IL235337 A0 IL 235337A0
- Authority
- IL
- Israel
- Prior art keywords
- multiple sclerosis
- high dose
- treating multiple
- laquinimod
- dose laquinimod
- Prior art date
Links
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 title 1
- 229960004577 laquinimod Drugs 0.000 title 1
- 201000006417 multiple sclerosis Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261641389P | 2012-05-02 | 2012-05-02 | |
| PCT/US2013/039090 WO2013166166A1 (en) | 2012-05-02 | 2013-05-01 | Use of high dose laquinimod for treating multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL235337A0 true IL235337A0 (en) | 2014-12-31 |
Family
ID=49514859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL235337A IL235337A0 (en) | 2012-05-02 | 2014-10-26 | Treatment of sclerosis by a dose of laquinimod |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20130303569A1 (enExample) |
| EP (1) | EP2844255A4 (enExample) |
| JP (2) | JP2015515985A (enExample) |
| KR (1) | KR20150013658A (enExample) |
| CN (2) | CN104284663A (enExample) |
| AR (1) | AR090885A1 (enExample) |
| AU (1) | AU2013256352A1 (enExample) |
| BR (1) | BR112014027010A2 (enExample) |
| CA (1) | CA2870684A1 (enExample) |
| CL (1) | CL2014002935A1 (enExample) |
| EA (1) | EA201492010A1 (enExample) |
| HK (1) | HK1206246A1 (enExample) |
| IL (1) | IL235337A0 (enExample) |
| MX (1) | MX2014013039A (enExample) |
| PE (1) | PE20150161A1 (enExample) |
| PH (1) | PH12014502447A1 (enExample) |
| SG (1) | SG11201406594UA (enExample) |
| TW (2) | TW201347762A (enExample) |
| UY (1) | UY34775A (enExample) |
| WO (1) | WO2013166166A1 (enExample) |
| ZA (1) | ZA201408820B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2766020A4 (en) | 2011-10-12 | 2015-04-01 | Teva Pharma | TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD |
| CN106063787A (zh) | 2012-02-03 | 2016-11-02 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| US9284276B2 (en) | 2012-02-16 | 2016-03-15 | Teva Pharmaceutical Industries, Ltd. | N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof |
| US20130259856A1 (en) * | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| AU2013329348A1 (en) * | 2012-10-12 | 2015-05-28 | Teva Pharmaceutical Industries Ltd. | Laquinimod for reducing thalamic damage in multiple sclerosis |
| BR112015010193A2 (pt) | 2012-11-07 | 2017-07-11 | Teva Pharma | sais de amina de laquinimod |
| CN105163737A (zh) * | 2013-02-15 | 2015-12-16 | 梯瓦制药工业有限公司 | 用拉喹莫德治疗多发性硬化症 |
| MX2015011627A (es) | 2013-03-14 | 2016-05-16 | Teva Pharma | Cristales de laquinimod sodico y proceso mejorado para la elaboracion de los mismos. |
| AR098924A1 (es) * | 2013-12-23 | 2016-06-22 | Teva Pharma | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y teriflunomida |
| SG11201608674UA (en) | 2014-04-29 | 2016-11-29 | Teva Pharma | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
| WO2017027512A1 (en) * | 2015-08-13 | 2017-02-16 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod to treat traumatic brain injury |
| US20190108912A1 (en) * | 2017-10-05 | 2019-04-11 | Iquity, Inc. | Methods for predicting or detecting disease |
| JP7724151B2 (ja) * | 2018-07-20 | 2025-08-15 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 多発性硬化症の治療及び予防方法における使用のための置換されたアミノ－ピリミジン化合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| EP1797109B1 (en) * | 2004-09-09 | 2016-02-24 | Yeda Research And Development Co., Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof |
| WO2007146331A1 (en) * | 2006-06-12 | 2007-12-21 | Teva Pharmaceutical Industries, Ltd. | Tannate salt form of polypeptide mixtures, their preparation and use |
| KR20120037477A (ko) * | 2009-06-19 | 2012-04-19 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드를 이용한 다발경화증의 치료 |
| EP2523668A1 (en) * | 2010-01-13 | 2012-11-21 | Ramot at Tel-Aviv University Ltd | Treatment of multiple sclerosis |
| EP2766020A4 (en) * | 2011-10-12 | 2015-04-01 | Teva Pharma | TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD |
| CN105163737A (zh) * | 2013-02-15 | 2015-12-16 | 梯瓦制药工业有限公司 | 用拉喹莫德治疗多发性硬化症 |
-
2013
- 2013-04-29 TW TW102115308A patent/TW201347762A/zh unknown
- 2013-04-29 TW TW106117959A patent/TW201804997A/zh unknown
- 2013-04-29 AR ARP130101459A patent/AR090885A1/es unknown
- 2013-04-30 UY UY0001034775A patent/UY34775A/es not_active Application Discontinuation
- 2013-05-01 PE PE2014001911A patent/PE20150161A1/es not_active Application Discontinuation
- 2013-05-01 US US13/874,537 patent/US20130303569A1/en not_active Abandoned
- 2013-05-01 CN CN201380022530.XA patent/CN104284663A/zh active Pending
- 2013-05-01 HK HK15106789.5A patent/HK1206246A1/xx unknown
- 2013-05-01 SG SG11201406594UA patent/SG11201406594UA/en unknown
- 2013-05-01 BR BR112014027010A patent/BR112014027010A2/pt not_active IP Right Cessation
- 2013-05-01 EA EA201492010A patent/EA201492010A1/ru unknown
- 2013-05-01 WO PCT/US2013/039090 patent/WO2013166166A1/en not_active Ceased
- 2013-05-01 AU AU2013256352A patent/AU2013256352A1/en not_active Abandoned
- 2013-05-01 JP JP2015510436A patent/JP2015515985A/ja not_active Withdrawn
- 2013-05-01 CA CA2870684A patent/CA2870684A1/en not_active Abandoned
- 2013-05-01 MX MX2014013039A patent/MX2014013039A/es unknown
- 2013-05-01 CN CN201610240473.8A patent/CN105832733A/zh active Pending
- 2013-05-01 KR KR1020147033707A patent/KR20150013658A/ko not_active Withdrawn
- 2013-05-01 EP EP13784231.6A patent/EP2844255A4/en not_active Withdrawn
-
2014
- 2014-10-26 IL IL235337A patent/IL235337A0/en unknown
- 2014-10-29 CL CL2014002935A patent/CL2014002935A1/es unknown
- 2014-10-31 PH PH12014502447A patent/PH12014502447A1/en unknown
- 2014-12-02 ZA ZA2014/08820A patent/ZA201408820B/en unknown
-
2015
- 2015-06-05 US US14/731,971 patent/US20150265592A1/en not_active Abandoned
- 2015-09-15 US US14/854,849 patent/US20160000775A1/en not_active Abandoned
-
2017
- 2017-07-21 JP JP2017141409A patent/JP2017222691A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| HK1206246A1 (en) | 2016-01-08 |
| EP2844255A1 (en) | 2015-03-11 |
| CN104284663A (zh) | 2015-01-14 |
| US20150265592A1 (en) | 2015-09-24 |
| MX2014013039A (es) | 2015-02-04 |
| TW201804997A (zh) | 2018-02-16 |
| US20130303569A1 (en) | 2013-11-14 |
| CN105832733A (zh) | 2016-08-10 |
| PE20150161A1 (es) | 2015-02-22 |
| WO2013166166A1 (en) | 2013-11-07 |
| AU2013256352A1 (en) | 2014-11-27 |
| PH12014502447A1 (en) | 2015-01-12 |
| JP2017222691A (ja) | 2017-12-21 |
| KR20150013658A (ko) | 2015-02-05 |
| SG11201406594UA (en) | 2014-11-27 |
| TW201347762A (zh) | 2013-12-01 |
| CA2870684A1 (en) | 2013-11-07 |
| ZA201408820B (en) | 2016-06-29 |
| AR090885A1 (es) | 2014-12-10 |
| BR112014027010A2 (pt) | 2017-06-27 |
| CL2014002935A1 (es) | 2015-03-06 |
| EA201492010A1 (ru) | 2015-06-30 |
| US20160000775A1 (en) | 2016-01-07 |
| JP2015515985A (ja) | 2015-06-04 |
| EP2844255A4 (en) | 2015-10-14 |
| UY34775A (es) | 2013-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201408820B (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| SI2879672T1 (sl) | Kombinirana terapija za zdravljenje multiple skleroze | |
| KR102297388B9 (ko) | 대사장애를 치료하기 위한 아커만시아의 용도 | |
| IL237138A0 (en) | Methods of administration of pirfenidone therapy | |
| IL252547A0 (en) | Treatment of multiple sclerosis using laquinimod | |
| LT2857019T (lt) | Išsėtinės sklerozės gydymo būdas | |
| IL234813A0 (en) | Methods for increasing the efficacy of cd37-based therapy | |
| IL227972A0 (en) | Use of glycopyrrolate to treat tachycardia | |
| IL240014A0 (en) | Treatment of multiple sclerosis using laquinimod | |
| PL2812013T3 (pl) | Formulacja do leczenia ibs | |
| PL3524260T3 (pl) | Kompozycje farmaceutyczne do leczenia braku apetytu | |
| ZA201408062B (en) | Compositions and methods for the treatment of multiple sclerosis | |
| PL2938350T3 (pl) | Formulacja medyczna do leczenia hipercholesterolemii | |
| GB201214877D0 (en) | Compounds for treatments of tumors | |
| IL236718A (en) | Vegfr-3 inhibitors for the preparation of drugs for the treatment of liver carcinoma | |
| IL244620A0 (en) | A drug combination including laquinimod for the treatment of multiple sclerosis | |
| ZA201409502B (en) | Composition for treatment of warts | |
| HK1225291A1 (en) | Laquinimod combination therapy for treatment of multiple sclerosis | |
| HUE039044T2 (hu) | Gyógyászati kompozíció sclerosis multiplex kezelésére | |
| IL228464A (en) | Quinolone analogues for use in the preparation of MS drugs |